Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.68 |
| ▸ | IDO1 | P14902 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TTK | P33981 | 2/20 | 0.62 |
| ▸ | ALPL | P05186 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.62 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.53 |
| ▸ | ITK | Q08881 | 2/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.49 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029371 | 0.84 | LRRK2 (0.54) | LRRK2IDO1KDM4EGAAALDH1A1 | |
| SCHEMBL1672674 | 0.83 | IDO1 (0.78) | LRRK2IDO1KDM4EGAAALDH1A1 | |
| SCHEMBL1328336 | 0.81 | LRRK2 (1.00) | LRRK2IDO1KDM4EGAAALDH1A1 | |
| SCHEMBL30316298 | 0.81 | LRRK2 (1.00) | LRRK2IDO1KDM4EGAAALDH1A1 | |
| SCHEMBL10452107 | 0.79 | LRRK2 (0.62) | LRRK2IDO1KDM4EGAAALDH1A1 | |
| SCHEMBL855531 | 0.77 | ALDH1A1 (1.00) | LRRK2IDO1KDM4EGAAALDH1A1 | |
| SCHEMBL30768403 | 0.77 | ALDH1A1 (1.00) | LRRK2IDO1KDM4EGAAALDH1A1 | |
| SCHEMBL4219256 | 0.77 | PDPK1 (0.54) | LRRK2IDO1MAP2K4ITKFGFR1 | |
| SCHEMBL10533662 | 0.76 | IDO1 (0.74) | LRRK2IDO1KDM4EGAAALDH1A1 | |
| SCHEMBL17922026 | 0.76 | LRRK2 (0.41) | LRRK2IDO1KDM4EGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2708556-B1 | PHARMACEUTICAL COMPOSITION FOR THE USE IN A COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF C-MET OR ANGIOGENESIS FACTOR INDUCED DISEASES | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-11-07 | — | — | EP | claimed |
| US-9931400-B2 | Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-04-03 | — | — | US | claimed |
| US-20140086926-A1 | METHOD OF COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF C-MET OR ANGIOGENESIS FACTOR INDUCED DISEASES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-03-27 | — | — | US | claimed |
| EP-2708556-A1 | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of C-Met or angiogenesis factor induced diseases | Samsung Electronics Co., Ltd (KR) | 2014-03-19 | — | — | EP | claimed |
| EP-4743106-A1 | METHODS OF USING THE BRAIN-DERIVED OSTEOGENIC FACTOR CCN3 FOR TREATMENT OF BONE AND CARTILAGE DEGENERATION | The Regents of University of California (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4719365-A1 | COMBINATION THERAPY WITH A MTOR INHIBITOR AND A MULTI-TYROSINE KINASE INHIBITOR FOR TREATING SOFT TISSUE SARCOMA | Aadi Bioscience, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025101807-A1 | TREATMENT OF GLIOMAS WITH CHIMERIC ANTIGEN RECEPTOR T CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025049342-A1 | METHODS OF USING THE BRAIN-DERIVED OSTEOGENIC FACTOR CCN3 FOR TREATMENT OF BONE AND CARTILAGE DEGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250074981-A1 | COMBINATION THERAPY WITH DEXAMETHASONE AND TUMOR-SPECIFIC T CELL ENGAGING MULTI-SPECIFIC ANTIBODIES FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-03-06 | — | — | US | disclosed |
| WO-2024243413-A1 | COMBINATION THERAPY WITH A MTOR INHIBITOR AND A MULTI-TYROSINE KINASE INHIBITOR FOR TREATING SOFT TISSUE SARCOMA | AADI BIOSCIENCE, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240270854-A1 | ENGINEERED BMP2 SURROGATE PROTEINS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-08-15 | — | — | US | disclosed |
| US-20240181135-A1 | BIOCHEMICAL ACTIVATION OF DYSFUNCTIONAL SKELETAL STEM CELLS FOR SKELETAL REGENERATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-06-06 | — | — | US | disclosed |
| WO-2009140549-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-1976529-A4 | ANG2 AND VEGF INHIBITOR COMBINATIONS | AMGEN INC (US) | 2009-07-22 | — | — | EP | disclosed |
| CN-101374522-A | ANG2 and VEGF inhibitor combinations | AMGEN INC (US) | 2009-02-25 | — | — | CN | disclosed |
| EP-1976529-A2 | ANG2 AND VEGF INHIBITOR COMBINATIONS | Amgen Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1915151-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | Amgen, Inc (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007089445-A2 | ANG2 AND VEGF INHIBITOR COMBINATIONS | AMGEN INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006102504-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | AMGEN INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060216288-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216288-A1 | Combinations for the treatment of cancer | TP53, VHL, FOLR2 | LRRK2 4710/4885IDO1 3718/4885KDM4E 3077/4885 |
| US-20240270854-A1 | ENGINEERED BMP2 SURROGATE PROTEINS | BMP2, BMPR1A, BMPR2 | LRRK2 1261/4885IDO1 1133/4885KDM4E 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.